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Abstract
Background: Most clinical research investigated prognos-
tic biomarkers for their ability to predict cardiovascular 
events or mortality. It is unknown whether biomarkers 
allow prediction of quality of life (QoL) after survival of the 
acute event. Herein, we investigated the prognostic poten-
tial of well-established inflammatory/cardiovascular blood 
biomarkers including white blood cells (WBC), C-reactive 
protein (CRP), procalcitonin (PCT), pro-adrenomedullin 
(proADM) and pro-atrial natriuretic peptide (proANP) 
in regard to a decline in QoL in a well-defined cohort of 
patients with community-acquired pneumonia (CAP).
Methods: Within this secondary analysis including 753 
patients with a final inpatient diagnosis of CAP from a 
multicenter trial, we investigated associations between 
admission biomarker levels and decline in QoL assessed 
by the EQ-5D health questionnaire from admission to day 
30 and after 6 years.
Results: Admission proADM and proANP levels signifi-
cantly predicted decline of the weighted EQ-5D index 
after 30 days (n = 753) with adjusted odds ratios (ORs) of 
2.0 ([95% CI 1.1–3.8]; p = 0.027) and 3.7 ([95% CI 2.2–6.0]; 
p < 0.001). Results for 6-year outcomes (n = 349) were 
similar with ORs of 3.3 ([95% CI 1.3–8.3]; p = 0.012) and 
6.2 ([95% CI 2.7–14.2]; p < 0.001). The markers were asso-
ciated with most of the different QoL dimensions includ-
ing mobility, self-care, and usual activities, but not pain/
discomfort and to a lesser degree anxiety/depression and 
the visual analogue scale (VAS). Initial WBC, PCT and CRP 
values did not well predict QoL at any time point.
Conclusions: ProADM and proANP accurately predict 
short- and long-term decline in QoL across most dimen-
sions in CAP patients. It will be interesting to reveal under-
lying physiopathology in future studies.
Keywords: anxiety; community-acquired pneumonia; 
C-reactive protein; depression; discomfort; EQ-5D index; 
mobility; pain; pro-adrenomedullin; pro-atrial natriuretic 
peptide; procalcitonin; quality of life; self-care; usual 
activities; VAS; white blood cells.
Introduction
Community-acquired pneumonia (CAP) is the leading 
cause of death from infectious disease [1], and is respon-
sible for high mortality, morbidity, and costs worldwide 
[2, 3]. Pneumonia is not only associated with high short-
term mortality [4, 5], but even more substantial long-
term mortality rates in patients surviving an initial CAP 
episode, as compared to the general population and to 
patients suffering from other infections, respectively [6–
11]. In addition, CAP is associated with a higher short- and 
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long-term risk of adverse cardiovascular events compared 
to controls [12], and pneumonia has lately been proposed 
to be an independent cardiovascular risk factor [12]. 
Importantly, quality of life (QoL) in individuals surviving 
a CAP episode has become an important health care indi-
cator and should also be considered when looking at CAP 
outcomes.
Much research has focused on short- and long-term 
outcome prognostication in the CAP patient population. 
This may help to better guide initial site-of-care decisions, 
and optimize discharge strategies and post-discharge out-
patient management. In addition to clinical risk scores, 
such as the pneumonia severity index (PSI) [13], several 
inflammatory and/or cardiovascular blood biomarkers 
such as white blood cells (WBC), C-reactive protein (CRP), 
procalcitonin (PCT), pro-adrenomedullin (proADM), as 
well as pro-atrial natriuretic peptide (proANP) have been 
found helpful for risk prediction [6, 14–20]. Particularly, 
proADM [9, 6, 21–30], proANP [9, 6, 25, 31–33] and PCT [10, 
22, 25, 31, 34–36] have been associated with risk for short- 
and long-term all-cause mortality as well as other adverse 
outcomes, such as severity of illness, admission to the 
intensive care unit (ICU), and disease-specific complica-
tions. Yet, there is insufficient evidence whether these 
clinical parameters and blood biomarkers are also helpful 
in predicting more subjective QoL outcomes: mens sana in 
corpore sano?
Herein, our aim was to study prognostic biomark-
ers for their ability to predict a decline in QoL in a well-
defined cohort of CAP patients. The early and accurate 
identification of patients being at risk for a decline in 
QoL after an index hospitalization for CAP may optimize 
patient satisfaction, inhospital and discharge manage-
ment, and improve our pathophysiological understanding 
of this disease.
Materials and methods
Aims
The prognostic accuracy of previously published inflammatory 
and cardiovascular blood biomarkers was investigated to predict a 
decline in QoL in the short-term (30 days) and long-term (6 years).
Study design and setting
This is a secondary analysis from a prospective randomized-con-
trolled, multi-center trial performed at six Swiss secondary or tertiary 
care centers between October 2006 and March 2008 [37]. A detailed 
study protocol of the initial trial has been published elsewhere [38]. 
Briefly, from a total of 1825 potential patients admitted to the emer-
gency department (ED), 925 subjects with a final inpatient diagnosis 
of CAP were included on admission. The aim of the initial prospec-
tive, multicenter, randomized-controlled trial was to assess the 
efficacy and safety of PCT guided antibiotic therapy compared to 
standard guidelines without using PCT data [39–41] in hospitalized 
patients with lower respiratory tract infections [37].
The study protocol was approved by the Ethics Committee of the 
University of Basel as well as by all Local Ethics Committees, writ-
ten informed consent was provided by all participants for the initial 
trial, including agreement to use their data anonymized in secondary 
analyses.
Selection and assessment of participants
Inclusion criteria were age  > 18  years and final diagnosis of CAP 
with an infiltrate on chest X-ray [37, 40, 42]. Exclusion cirteria were 
language restriction or dementia precluding patients from provid-
ing written informed consent, a terminal condition, intravenous 
drug abuse as well as hospital-acquired pneumonia. Additionally, 
patients were excluded due to severe immunosuppression or long-
term antibiotic therapy on admission, while being a recipient of cor-
ticosteroids or short-term antibiotic pretreatment were allowed.
Patient assessment included clinical and biochemical evalu-
ation upon admission to the ED and throughout the period of hos-
pitalization. The standardized baseline characteristics comprised 
medical history, comorbidities (identified either through patient self-
report or medical chart review), vital signs, laboratory values, chest 
X-ray and medication. To assess disease severity, the PSI [13] and 
the confusion, urea, respiratory rate, blood pressure, age  > 65 years 
(Curb-65 score) [40] – validated risk assessment tools to categorize 
CAP patients into different risk classes – were calculated upon ED 
admission. Discharge decision concerning patients enrolled in the 
study was completely left to the treating physicians without interfer-
ence of the study team.
For the present analysis, all of initially included 925 patients with 
a final inpatient diagnosis of CAP were eligible for analysis, if they had 
available information on admission blood biomarker levels and if they 
survived until the follow-up period for completion of the QoL assess-
ment performed at 30 days and 6 years. After exclusion of 50 non-sur-
vivors (5%) at day 30 and 417 non-survivors (45%) at 6 years, as well as 
122 (13%) and 159 (17%) survivors with missing information on the QoL 
assessment, the final cohort consists of 753 of 925 patients (81%) for the 
day 30 analysis, and 349 of 925 patients (38%) for the 6-year analysis.
Analysis of blood biomarkers
Within the initial trial, blood samples for later measurement of dif-
ferent biomarkers were collected upon admission to the ED and 
throughout the hospitalization period. In the present analysis, we 
focused on five inflammatory and/or cardiovascular markers (WBC, 
CRP, PCT, proADM and proANP). Determination of WBC, CRP and 
PCT was done during clinical routine, while proADM and proANP 
were determined by batch analysis only after study completion. For 
quantification of PCT levels, an automated, sensitive assay (KRYP-
TOR PCT; Thermo Scientific Biomarkers [formerly BRAHMS AG], 
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Table 2: Initial blood biomarker levels alone or combined with a clinical model to predict a decline in quality of life, measured by the 
weighted EQ-5D index, in CAP: univariate/multivariate logistic regression analyses and ROC curve analyses of accuracy.
 
 
Decline in EQ-5D index
30 days vs. inhospital (n = 753)   6 years vs. inhospital (n = 349)
WBC
 Univariate and multivariate analyses
  Univariate model   1.09 (0.50–2.37)  p = 0.829   1.03 (0.34–3.09)  p = 0.960
  Combined modela   1.24 (0.55–2.80)  p = 0.598   1.16 (0.33–4.02)  p = 0.815
 Prognostic accuracy
  Univariate model   0.49 (0.44–0.53)   0.48 (0.42–0.54)
CRP
 Univariate and multivariate analyses
  Univariate model   0.88 (0.63–1.24)  p = 0.470   1.05 (0.66–1.65)  p = 0.845
  Combined modela   0.86 (0.60–1.22)  p = 0.388   1.04 (0.63–1.71)  p = 0.889
 Prognostic accuracy
  Univariate model   0.48 (0.43–0.53)   0.49 (0.43–0.55)
PCT
 Univariate and multivariate analyses
  Univariate model   0.96 (0.78–1.18)  p = 0.716   1.20 (0.92–1.57)  p = 0.171
  Combined modela   0.97 (0.79–1.20)  p = 0.809   1.22 (0.91–1.64)  p = 0.186
 Prognostic accuracy
  Univariate model   0.49 (0.44–0.53)   0.55 (0.49–0.61)
ProADM
 Univariate and multivariate analyses
  Univariate model   1.64 (0.91–2.94)  p = 0.100   2.76 (1.23–6.20)  p = 0.014
  Combined modela   2.03 (1.08–3.80)  p = 0.027   3.28 (1.30–8.29)  p = 0.012
 Prognostic accuracy
  Univariate model   0.54 (0.50–0.58)   0.59 (0.53–0.65)
ProANP
 Univariate and multivariate analyses        
  Univariate model   2.58 (1.64–4.04)  p < 0.001   3.50 (1.75–7.01)  p < 0.001
  Combined modela   3.66 (2.22–6.03)  p < 0.001   6.16 (2.68–14.20)  p < 0.001
 Prognostic accuracy
  Univariate model   0.60 (0.56–0.65)   0.62 (0.56–0.67)
Data for univariate and multivariate analyses are presented as OR (95% CI), p-Value; p-Values are considered statistically significant at 
p < 0.05. Data regarding prognostic accuracy are presented as AUC (95% CI); an AUC of 0.5 indicates coin-toss accuracy, while 1.0 indicates 
100% accuracy. Bold values indicate statistical significance and prognostic accuracy better than coin-toss, respectively. AUC, area under the 
receiver operating characteristic curve; CI, confidence interval; CRP, C-reactive protein; EQ-5D, EuroQol 5 dimensions; OR, odds ratio; PCT, 
procalcitonin; ProADM, proadrenomedullin; ProANP, pro-atrial natriuretic peptide; ROC, receiver operating characteristic (curve); WBC, white 
blood cell count. aCombined model is adjusted for baseline values of each dimension of the EQ-5D descriptive system comprising mobility, 
self-care, usual activities, pain/discomfort, anxiety/depression.
 Henningsdorf, Germany) was used, showing a lower detection limit 
of 0.02 μg/L and a functional sensitivity of 0.06 μg/L. Measurements 
of proADM plasma levels were performed by a sandwich immunoas-
say with a lower detection limit of 0.08 nmol/L [43, 44]. Determina-
tion of proANP plasma levels was performed by another sandwich 
immunoassay (BRAHMS AG, Henningsdorf/Berlin,  Germany) with 
a lower detection limit of 4.3 pmol/L and a functional sensitivity of 
11 pmol/L, as previously described [45].
Patient outcomes
The primary endpoint of this study was a decline in QoL from hospi-
tal admission (baseline) to day 30 and after 6 years. For this purpose, 
QoL was measured with the EQ-5D health questionnaire as recom-
mended [46–48] in the ED on the day of admission – assessing QoL of 
the past 7 days – and by telephone interviews during the follow-up. 
The EQ-5D comprises the five-item tool EQ-5Dself-classifier, a descriptive 
system, which assesses the health-related QoL along the follow-
ing five dimensions: ‘mobility’, ‘self-care’, ‘usual activities’, ‘pain/
discomfort’ and ‘anxiety/depression’. Each domain is expressed by 
three severity levels. Importantly, the EQ-5D instrument provides 
calculation of a weighted country-specific single index value [49], 
considered as primary endpoint. It additionally includes the EQ VAS 
recording the patients’ self-rated health state on a vertical scale as a 
quantitative measurement.
Secondary endpoints were defined as a decline in the different 
5 dimensions of EQ-5D and in the self-reported health state using the 
EQ VAS after 30 days and 6 years post-discharge.
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To ascertain outcomes, blinded medical students performed 
structured phone interviews at 30  days after enrolment as well 
as after a median of 6.1  years [interquartile range (IQR) 5.6–6.5]. If 
patients or their family members could not be contacted, the treating 
primary care physicians were called.
Statistical analyses
Statistical analyses were conducted using STATA 12.1 (Stata Corp, 
College Station, TX, USA). A p-Value  < 0.05 indicated statistical 
significance. Description of the study population was performed 
by descriptive statistics including medians with IQRs to express 
continuous variables, and frequencies (percentages) for categori-
cal variables. Wilcoxon rank-sum test was used for two-group 
comparison, whereas frequency comparison was done by chi-
square test.
Univariate and multivariate logistic regression analyses were 
performed to assess the association of blood biomarker values with 
a decline in QoL from baseline to day 30 and after 6 years. Results 
are reported as odds ratios (ORs) with 95% confidence intervals (95% 
CIs) and significance levels calculated by chi-square test. Models 
were adjusted for either age and gender, important comorbidities 
(coronary heart disease, cerebrovascular insult, chronic renal fail-
ure, neoplastic disease) or baseline QoL (including each dimension 
of the EQ-5D descriptive system into the model). Before entering 
regression models, blood biomarker levels were log-transformed due 
to a skewed distribution.
Results
Baseline characteristics
Baseline characteristics of the entire cohort and strati-
fied by the primary endpoint, i.e. the change in QoL at 
30 days and 6 years, are presented in Table 1. The study 
included 753 patients for the analysis after 30 days and 
349 after 6  years. A total of 29% of patients showed a 
decline in QoL at 30 days and 42% after 6 years. Median 
age of the entire cohort was 72 years, and patients had a 
high burden of comorbidities with 19% (142) of patients 
suffering from coronary heart disease, 16% (121) con-
gestive heart failure, 20% (151) chronic renal failure, 
17% (126) diabetes mellitus and 12% (93) neoplastic 
disease.
Patients with a decline in QoL had higher age as com-
pared to individuals with no decline at both time points. 
There was no difference in terms of gender and comor-
bidities except for chronic renal failure (26% vs. 18%) and 
neoplastic disease (12% vs. 5%). In regard to biomarkers, 
discharge values of proADM and both admission and dis-
charge levels of proANP were increased in patients with a Ta
bl
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decline in QoL. In contrast, there were no differences in 
levels of WBC, CRP and PCT.
Associations between blood biomarker 
levels and quality of life
Table 2 shows the results of uni- and multivariate logistic 
regression analyses assessing associations of initial blood 
biomarker values and a decline in QoL after 30 days and 
6 years. In the adjusted model including adjustment for 
baseline QoL, significant associations of initial proADM 
and proANP levels with a decline in the weighted EQ-5D 
index after a 30-day follow-up period was found with ORs 
of 2.0 ([95% CI 1.1–3.8]; p = 0.027) and 3.7 ([95% CI 2.2–6.0]; 
p < 0.001). For a decline over 6 years, results were similar 
with ORs of 3.3 ([95% CI 1.3–8.3]; p = 0.012) and 6.2 ([95% 
CI 2.7–14.2]; p < 0.001) for proADM and proANP. As pre-
sented in Table 2, no associations were found for initial 
values of WBC, CRP, PCT.
In a secondary analysis, we also focused on a decline 
in the different QoL dimensions as well as a decline in 
VAS (Tables 3 and 4). Regression analyses demonstrated, 
that proADM and proANP levels were significantly asso-
ciated with worsening in ‘mobility’, ‘self-care’ and ‘usual 
activities’ over both 30  days and 6 years. This associa-
tion remained robust after adjustment for baseline QoL 
(Table 3). As presented in Table 4, only proANP was asso-
ciated with a decline in the ‘anxiety/depression’ dimen-
sion, while proADM was not. In addition, no associations 
with measured biomarker levels were found for a decline 
in ‘pain/discomfort’ and the VAS after model adjustment.
We also calculated area under the receiver operating 
curve (AUC) of the different markers and decline of QoL 
(Tables 2–4), as well as prognostic accuracy measures 
including sensitivities, specificities, negative and positive 
predictive values. For proADM, these measures showed 
at an optimal cut-off of 1.33 nmol/L a sensitivity of 44% 
and specificity of 62% with positive and negative predic-
tive values of 33% and 73%, respectively. At the optimal 
cut-off of 168 nmol/L of proANP, the sensitivity was 61% 
with a specificity of 59% and positive and negative predic-
tive values of 39% and 78%.
To further illustrate these findings, results of adjusted 
logistic regression models are presented in forest plots 
(Figures 1–4), demonstrating blood biomarker values 
according to the change in QoL.
We also investigated discharge as well as high peak 
levels of the respective blood biomarkers, and their 
association with QoL, showing similar results (data not 
shown).
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Figure 1: Forest plot showing odds ratios of blood biomarker values according to the change in QoL, measured by the EQ-5D index, over a 
30-day and 6-year follow-up period.
Odds ratios  > 1 reflect a positive association between biomarker levels and worsening of QoL. Models are adjusted for baseline values of 
each dimension of the EQ-5D descriptive system comprising mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 
CAP, community-acquired pneumonia; CI, confidence interval; CRP, C-reactive protein; EQ-5D, EuroQol 5 dimensions; OR, odds ratio; PCT, 
 procalcitonin; ProADM, proadrenomedullin; ProANP, pro-atrial natriuretic peptide; QoL, quality of life; WBC, white blood cell count.
Discussion
The findings of this first study investigating the ability of 
circulating inflammatory and cardiovascular biomarker 
levels to predict a decline in QoL in CAP patients are 
two-fold. First, proADM and proANP predicted worsen-
ing in the weighted QoL index over 30 days and 6 years 
in patients hospitalized for CAP. Other prognostic inflam-
matory markers including WBC, CRP and PCT did not 
show any significant association. Second, regarding the 
different dimensions of QoL as assessed with the EQ-5D 
descriptive system, changes in ‘mobility’, ‘self-care’ and 
‘usual activities’ were strongly associated with high levels 
of proADM and proANP in the short- and long-term, 
whereas impairment in the domain ‘pain/discomfort’ and 
the VAS showed no association after model adjustment.
Multiple studies have demonstrated that suffering 
from CAP is an indicator of poor prognosis with impaired 
short- and long-term outcome [4–11]. CAP per se is asso-
ciated with an increased rate of adverse cardiovascu-
lar events [12]. On the one hand comorbidities such as 
cardiac disease and malignancy might be the reasons for 
this poor prognosis, on the other hand, pneumonia itself 
has recently been proposed to be an independent cardio-
vascular risk predictor [12]. Thereby inflammatory host 
response might act as a relevant contributor by modify-
ing the ratio between prothrombotic and antithrombotic 
factors. Due to this hard endpoints, it is crucial to pay 
attention to patients’ subjective QoL in time following a 
CAP episode. Early identification of those being at risk for 
a decline in QoL could lead to improved health state by 
providing individual medical resources such as physical 
therapy, prescription of a walking stick/frame, registra-
tion at a retirement or nursing home as well as, e.g. psy-
chological support even at an early stage of disease. This 
in turn might result in a reduction of rehospitalization 
rates and outpatient visits, potentially lowering health 
care costs. The present analysis of a large, well-character-
ized cohort provides novel insights into the prediction of 
patient-specific QoL outcomes in hospitalized CAP and is 
thus worth mentioning.
Based on several clinical observational studies, cir-
culating proADM and proANP have lately emerged as 
useful prognostic tools regarding all-cause mortality, ICU 
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admission, severity of illness and disease-specific com-
plications in CAP [9, 6, 25, 31–33]. The present analysis 
expands these findings by demonstrating a relevant cor-
relation between high proADM and proANP levels and 
future decline in QoL in CAP patients. Since proADM 
acts as an immune regulatory peptide [50–54] as well as 
a potent vasodilatator [55,  56], and is upregulated due 
to hypoxia, inflammatory conditions, bacterial products 
and shear stress [51, 52, 57–60], it is tempting to speculate 
that the grade of respiratory insufficiency and the acute 
inflammatory host response during a CAP episode might 
have a relevant impact on patients’ QoL in the short- and 
long-term. Moreover, considering proADM as a cardio-
vascular peptide [55, 56], high circulating levels might 
indicate a chronic condition of vascular stress based on 
endothelial damage, again potentially resulting in future 
health state impairment. ANP, a member of the family of 
natriuretic peptides, regulates natriuresis and diuresis, 
and lowers systemic blood pressure [61, 62]; additionally, 
increased proANP concentrations have been observed 
in patients suffering from severe infections [63]. Thus, 
proADM and proANP may mirror both, the acute inflam-
matory response reflecting the actual state of disease, and 
the concomitance of cardiovascular comorbidities as a 
static component. It must be emphasized that results of 
logistic regression analyses according to the change in 
the EQ-5D index were similar for admission and discharge 
proADM and proANP levels, assuming discharge values to 
basically represent the chronic state of expression.
Considering the lower predictive ability of proADM 
and proANP according to ‘pain/discomfort’ and ‘anxiety/
depression’ compared to the other documented QoL 
domains, one could hypothesize that the former two 
dimensions underly other pathophysiological mecha-
nisms than the categories ‘mobility’, ‘selfcare’ and ‘usual 
activities’. It is likely, that discomfort and feelings of being 
depressed or anxious are rather influenced by psychologi-
cal and social factors, than by the state of inflammation 
or concomitant cardiovascular disease. This assumption 
needs verification in future studies. On the other hand, it 
WBC
CRP
PCT
ProADM
ProANP
WBC
CRP
PCT
ProADM
ProANP
0.92 (0.42, 2.03)
0.91 (0.63, 1.31)
1.11 (0.90, 1.36)
1.60 (0.86, 3.00)
1.47 (0.91, 2.36)
2.71 (0.08, 88.07)
0.47 (0.09, 2.46)
0.49 (0.17, 1.38)
2.96 (0.09, 101.99)
2.32 (0.19, 27.78)
Odds ratio (95% CI)
0.1 0 10 100 
VA
S 
(n=
64
4)
30
 d
ay
s 
vs
. i
nh
os
pi
ta
l
VA
S 
(n=
37
)
6 
ye
ar
s 
vs
. i
nh
os
pi
ta
l
Positive association of
biomarker values with
a decline in QoL
Negative association of
biomarker values with
a decline in QoL
Odds ratio
0.01
Figure 2: Forest plot showing odds ratios of blood biomarker values according to the change in QoL, measured by the EQ-VAS, over a 30-day 
and 6-year follow-up period.
Odds ratios  > 1 reflect a positive association between biomarker levels and worsening of QoL. Models are adjusted for baseline values of 
each dimension of the EQ-5D descriptive system comprising mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 
CAP, community-acquired pneumonia; CI, confidence interval; CRP, C-reactive protein; EQ-5D, EuroQol 5 dimensions; OR, odds ratio; PCT, 
 procalcitonin; ProADM, proadrenomedullin; ProANP, pro-atrial natriuretic peptide; QoL, quality of life; VAS, visual analogue scale; WBC, 
white blood cell count.
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Figure 3: Forest plot showing odds ratios of blood biomarker values according to the change in QoL, measured by the EQ-5D descriptive 
system, over a 30-day follow-up period (n = 753).
Odds ratios  > 1 reflect a positive association between biomarker levels and worsening of QoL. Models are adjusted for baseline values of 
each dimension of the EQ-5D descriptive system comprising mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 
CAP, community-acquired pneumonia; CI, confidence interval; CRP, C-reactive protein; EQ-5D, EuroQol 5 dimensions; OR, odds ratio; PCT, 
 procalcitonin; ProADM, proadrenomedullin; ProANP, pro-atrial natriuretic peptide; QoL, quality of life; WBC, white blood cell count.
should be taken into account, that pain and discomfort 
as well as anxiety and depression might exhibit a bigger 
variety during the day because of diurnal mood fluctua-
tion, making it difficult to collect data homogenously. 
Otherwise, we assume patients’ self-assessment in terms 
of current ‘mobility’, ‘selfcare and ‘usual activities’ to be 
more stable in the daytime and thus easier to quantify. 
Importantly, in adjusted regression models none of the 
analyzed blood biomarkers correlated with self-reported 
health-state by VAS in the months and years after a CAP 
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Figure 4: Forest plot showing odds ratios of blood biomarker values according to the change in QoL, measured by the EQ-5D descriptive 
system, over a 6-year follow-up period (n = 349).
Odds ratios  > 1 reflect a positive association between biomarker levels and worsening of QoL. Models are adjusted for baseline values of 
each dimension of the EQ-5D descriptive system comprising mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 
CAP, community-acquired pneumonia; CI, confidence interval; CRP, C-reactive protein; EQ-5D, EuroQol 5 dimensions; OR, odds ratio; PCT, 
 procalcitonin; ProADM, proadrenomedullin; ProANP, pro-atrial natriuretic peptide; QoL, quality of life; WBC, white blood cell count.
episode. Again, other potential predictors as well as the 
probable fluctuation intraday might have had an influ-
ence on the respective outcome.
The main strengths of this study include the well-
defined and characterized cohort of patients hospitalized 
for CAP, the long follow-up period of 6  years and the 
thorough and highly accurate biomarker measurement 
methods. The large sample size and the high number of 
primary endpoints in the short- and long-term (29% and 
42%, respectively) lead to high statistical power, which in 
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turn allows detecting even small differences in biomarker 
levels. Nevertheless, the following limitations require con-
sideration: First, the present study is a secondary analy-
sis and therefore rather hypothesis generating. Second, 
the initial trial was conducted in different secondary and 
tertiary care hospitals in Switzerland, and thus results 
may not be applicable to other settings such as primary 
or intensive care, and other countries. Third, due to the 
exclusion of non-survivors, we assume the herein ana-
lyzed cohort to comprise healthier subjects as compared 
to the CAP population usually treated in EDs. This sugges-
tion is in line with the observation that CAP non-survivors 
enrolled in the initial trial displayed a significantly higher 
concomitance of comorbidities and showed higher PSI 
values compared to survivors [6]. Thus, the present results 
might not unconditionally be generalizable to the severely 
ill. Due to the high number of non-survivors we did not 
do an analysis with imputation of the worst QoL value – 
namely death – for these patients as the analysis would 
have been strongly driven by mortality. In addition, within 
our analysis we focused specifically on patients suffering 
from CAP; further studies are required to validate these 
findings for other medical and surgical patient popula-
tions. Also, our baseline QoL may has been affected by the 
acute medical situation in the ED and may differ thus from 
later measurements using telephone interviews. Finally, 
since this was an observational study, it is only hypothesis 
generating and correlation does not imply causality.
Conclusions
In conclusion, proADM and proANP levels allowed accu-
rate short- and long-term prognostication regarding the 
change in QoL in hospitalized CAP. Importantly, proADM 
and proANP most accurately discriminate a decline in QoL 
as compared to WBC, CRP and PCT levels. An improved 
risk stratification in CAP regarding the change in QoL with 
an early risk-based, ‘personalized’ deployment of medical 
resources could potentially improve subsequent health 
state, reduce rehospitalization rates, decrease outpatient 
consultations, and may in turn contribute to a more cost-
effective patient management.
Acknowledgments: We are grateful to the emergency 
department, medical clinic, and central laboratory staff 
of the University Hospital Basel and the Cantonal Hos-
pitals Aarau, Liestal, Lucerne, and Muensterlingen, and 
the ‘Buergerspital’ Solothurn for their assistance and 
technical support. In particular, we thank all patients, 
their relatives and all local general practitioners who 
participated in this study. Finally, we acknowledge the 
ProHOSP Study Group for their important support. The 
ProHOSP study group included the following persons: 
Ursula Schild, RN, Katharina Regez, RN, Rita Bossart, RN, 
Robert Thomann, MD, Claudine Falconnier, MD, Marcel 
Wolbers, PHD, Stefanie Neidert, MD, Thomas Fricker, 
MD, Claudine Blum, MD, Thomas Bregenzer, MD, Claus 
Hoess, MD, Heiner C. Bucher, MD, Fabian Mueller, Jean-
nine Haeuptle, Roya Zarbosky, Rico Fiumefreddo, MD, 
Melanie Wieland, RN, Charly Nusbaumer, MD, Andres 
Christ, MD, Roland Bingisser, MD, Kristian Schneider, RN, 
Brigitte Walz, PhD, Verena Briner, MD, Dieter Conen, MD, 
Andreas Huber, MD, Jody Staehelin, MD, Aarau, Chantal 
Bruehlhardt, RN, Ruth Luginbuehl, RN, Agnes Muehle-
mann, PhD, Ineke Lambinon, Werner Zimmerli, MD, and 
Max Zueger, MD.
Author contributions: All the authors have accepted 
responsibility for the entire content of this submitted 
manuscript and approved submission.
Research funding: The main sources of funding for the 
investigator-initiated ProHOSP study were the Swiss 
National Science Foundation (grant SNF 3200BO-116177/1), 
Santé Suisse and the Gottfried and Julia Bangerter-Rhyner 
Foundation.
Employment or leadership: MC-C, BM and PS have 
received grants from B·R·A·H·M·S/Thermo and bioMé-
rieux; in addition, BM has served as a consultant to these 
companies. None of the other authors has any relevant 
industrial relationships.
Honorarium: None declared.
Competing interests: The funding organization(s) played 
no role in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; or in the 
decision to submit the report for publication.
References
1. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. 
Natl Vital Stat Rep 2008;56:1–120.
2. Brown PD, Lerner SA. Community-acquired pneumonia. Lancet 
1998;352:1295–302.
3. File TM. Community-acquired pneumonia. Lancet 2003;362:1991–
2001.
4. Menendez R, Torres A, Zalacain R, Aspa J, Martin Villasclaras JJ, 
Borderias L, et al. Risk factors of treatment failure in community 
acquired pneumonia: implications for disease outcome. Thorax 
2004;59:960–5.
5. Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, et al. 
Epidemiology of community-acquired pneumonia in adults: a 
population-based study. Eur Respir J 2000;15:757–63.
Brought to you by | Universitaetsbibliothek Basel
Authenticated
Download Date | 4/29/19 4:29 PM
Nickler et al.: Blood biomarkers to predict quality of life in community-acquired pneumonia      1845
6. Alan M, Grolimund E, Kutz A, Christ-Crain M, Thomann R, Falcon-
nier C, et al. Clinical risk scores and blood biomarkers as predic-
tors of long-term outcome in patients with community-acquired 
pneumonia: a 6-year prospective follow-up study. J Intern Med 
2015;278:174–84.
7. Restrepo MI, Faverio P, Anzueto A. Long-term prognosis in com-
munity-acquired pneumonia. Curr Opin Infect Dis 2013;26:151–8.
8. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky 
MR, et al. Understanding the inflammatory cytokine response 
in pneumonia and sepsis: results of the Genetic and Inflam-
matory Markers of Sepsis (GenIMS) Study. Arch Intern Med 
2007;167:1655–63.
9. Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, 
Schuetz P. Inflammatory responses predict long-term mor-
tality risk in community-acquired pneumonia. Eur Respir J 
2011;37:1439–46.
10. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zim-
merli W, Mueller B, et al. Prognostic value of procalcitonin in 
community-acquired pneumonia. Eur Respir J 2011;37:384–92.
11. Suter-Widmer I, Christ-Crain M, Zimmerli W, Albrich W, Mueller 
B, Schuetz P, et al. Predictors for length of hospital stay in 
patients with community-acquired pneumonia: results from a 
Swiss multicenter study. BMC Pulm Med 2012;12:21.
12. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, 
 Chirinos JA, Chang CC, et al. Association between hospitaliza-
tion for pneumonia and subsequent risk of cardiovascular 
disease. J Am Med Assoc 2015;313:264–74.
13. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, 
Singer DE, et al. A prediction rule to identify low-risk 
patients with community-acquired pneumonia. N Engl J Med 
1997;336:243–50.
14. Zhydkov A, Christ-Crain M, Thomann R, Hoess C, Henzen C, 
Werner Z, et al. Utility of procalcitonin, C-reactive protein and 
white blood cells alone and in combination for the prediction of 
clinical outcomes in community-acquired pneumonia. Clin Chem 
Lab Med 2015;53:559–66.
15. Schuetz P, Hausfater P, Amin D, Amin A, Haubitz S, Faessler L, 
et al. Biomarkers from distinct biological pathways improve 
early risk stratification in medical emergency patients: the mul-
tinational, prospective, observational TRIAGE study. Crit Care 
2015;19:377.
16. Kutz A, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, 
et al. Prognostic value of procalcitonin in respiratory tract infec-
tions across clinical settings. Crit Care 2015;19:74.
17. Grolimund E, Kutz A, Marlowe RJ, Vogeli A, Alan M, Christ-Crain 
M, et al. Long-term prognosis in COPD exacerbation: role of 
biomarkers, clinical variables and exacerbation type. COPD 
2015;12:295–305.
18. Debiane L, Hachem RY, Al Wohoush I, Shomali W, Bahu RR, Jiang 
Y, et al. The utility of proadrenomedullin and procalcitonin in 
comparison to C-reactive protein as predictors of sepsis and 
bloodstream infections in critically ill patients with cancer*. 
Crit Care Med 2014;42:2500–7.
19. Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E. Proc-
alcitonin decrease over 72 hours in US critical care units predicts 
fatal outcome in sepsis patients. Crit Care 2013;17:R115.
20. Schuetz P, Litke A, Albrich WC, Mueller B. Blood biomarkers 
for personalized treatment and patient management deci-
sions in community-acquired pneumonia. Curr Opin Infect Dis 
2013;26:159–67.
21. Suberviola B, Castellanos-Ortega A, Llorca J, Ortiz F, Iglesias D, 
Prieto B. Prognostic value of proadrenomedullin in severe sepsis 
and septic shock patients with community-acquired pneumonia. 
Swiss Med Wkly 2012;142:w13542.
22. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser 
R, Harbarth S, et al. Pro-adrenomedullin to predict severity and 
outcome in community-acquired pneumonia [ISRCTN04176397]. 
Crit Care 2006;10:R96.
23. Huang DT, Angus DC, Kellum JA, Pugh NA, Weissfeld LA, Struck 
J, et al. Midregional proadrenomedullin as a prognostic tool in 
community-acquired pneumonia. Chest 2009;136:823–31.
24. Kruger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T, 
et al. Cardiovascular and inflammatory biomarkers to predict 
short- and long-term survival in community-acquired pneumo-
nia: Results from the German Competence Network, CAPNETZ. 
Am J Respir Crit Care Med 2010;182:1426–34.
25. Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, 
Widmer I, et al. Prohormones for prediction of adverse medical 
outcome in community-acquired pneumonia and lower respira-
tory tract infections. Crit Care 2010;14:R106.
26. Albrich WC, Dusemund F, Ruegger K, Christ-Crain M, Zimmerli 
W, Bregenzer T, et al. Enhancement of CURB65 score with 
proadrenomedullin (CURB65-A) for outcome prediction in lower 
respiratory tract infections: derivation of a clinical algorithm. 
BMC Infect Dis 2011;11:112.
27. Bello S, Lasierra AB, Minchole E, Fandos S, Ruiz MA, Vera E, 
et al. Prognostic power of proadrenomedullin in community-
acquired pneumonia is independent of aetiology. Eur Respir J 
2012;39:1144–55.
28. Renaud B, Schuetz P, Claessens YE, Labarere J, Albrich W, 
Mueller B. Proadrenomedullin improves Risk of Early Admission 
to ICU score for predicting early severe community-acquired 
pneumonia. Chest 2012;142:1447–54.
29. Courtais C, Kuster N, Dupuy AM, Folschveiller M, Jreige R, 
Bargnoux AS, et al. Proadrenomedullin, a useful tool for risk 
stratification in high Pneumonia Severity Index score community 
acquired pneumonia. Am J Emerg Med 2013;31:215–21.
30. Gordo-Remartinez S, Calderon-Moreno M, Fernandez-Herranz J, 
Castuera-Gil A, Gallego-Alonso-Colmenares M, Puertas-Lopez C, 
et al. Usefulness of midregional proadrenomedullin to predict 
poor outcome in patients with community acquired pneumonia. 
PLoS One 2015;10:e0125212.
31. Kruger S, Ewig S, Kunde J, Hartmann O, Suttorp N, Welte T, et al. 
Pro-atrial natriuretic peptide and pro-vasopressin for predicting 
short-term and long-term survival in community-acquired pneu-
monia: results from the German Competence Network CAPNETZ. 
Thorax 2010;65:208–14.
32. Kruger S, Papassotiriou J, Marre R, Richter K, Schumann C, von 
Baum H, et al. Pro-atrial natriuretic peptide and pro-vasopressin 
to predict severity and prognosis in community-acquired pneu-
monia: results from the German competence network CAPNETZ. 
Intensive Care Med 2007;33:2069–78.
33. Muller B, Suess E, Schuetz P, Muller C, Bingisser R, Bergmann A, 
et al. Circulating levels of pro-atrial natriuretic peptide in lower 
respiratory tract infections. J Intern Med 2006;260:568–76.
34. Haeuptle J, Zaborsky R, Fiumefreddo R, Trampuz A, Steffen I, Frei 
R, et al. Prognostic value of procalcitonin in Legionella pneumo-
nia. Eur J Clin Microbiol Infect Dis 2009;28:55–60.
35. Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum 
H, et al. Procalcitonin predicts patients at low risk of death from 
Brought to you by | Universitaetsbibliothek Basel
Authenticated
Download Date | 4/29/19 4:29 PM
1846      Nickler et al.: Blood biomarkers to predict quality of life in community-acquired pneumonia
community-acquired pneumonia across all CRB-65 classes. Eur 
Respir J 2008;31:349–55.
36. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, 
et al. Diagnostic and prognostic accuracy of clinical and labora-
tory parameters in community-acquired pneumonia. BMC Infect 
Dis 2007;7:10.
37. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers 
M, Widmer I, et al. Effect of procalcitonin-based guidelines vs. 
standard guidelines on antibiotic use in lower respiratory tract 
infections: the ProHOSP randomized controlled trial. J Am Med 
Assoc 2009;302:1059–66.
38. Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, 
Falconnier C, et al. Procalcitonin guided antibiotic therapy and 
hospitalization in patients with lower respiratory tract infec-
tions: a prospective, multicenter, randomized controlled trial. 
BMC Health Serv Res 2007;7:102.
39. Gonzales R, Sande MA. Uncomplicated acute bronchitis. Ann 
Intern Med 2000;133:981–91.
40. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, 
Campbell GD, et al. Guidelines for the management of adults 
with community-acquired pneumonia. Diagnosis, assessment of 
severity, antimicrobial therapy, and prevention. Am J Respir Crit 
Care Med 2001;163:1730–54.
41. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, 
et al. Guidelines for the management of adult lower respiratory 
tract infections. Eur Respir J 2005;26:1138–80.
42. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, 
Dean NC, et al. Infectious Diseases Society of America/American 
Thoracic Society consensus guidelines on the management 
of community-acquired pneumonia in adults. Clin Infect Dis 
2007;44(Suppl 2):S27–72.
43. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification 
of an Adrenomedullin precursor fragment in plasma of sepsis 
patients. Peptides 2004;25:1369–72.
44. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement 
of midregional proadrenomedullin in plasma with an immunolu-
minometric assay. Clin Chem 2005;51:1823–9.
45. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immuno-
luminometric assay for the midregion of pro-atrial natriuretic 
peptide in human plasma. Clin Chem 2004;50:234–6.
46. Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D–a generic 
quality of life measure-is a useful instrument to measure quality 
of life in patients with Parkinson’s disease. J Neurol Neurosurg 
Psychiatry 2000;69:67–73.
47. EuroQol G. EuroQol–a new facility for the measurement of 
health-related quality of life. Health Policy 1990;16:199–208.
48. Brooks R. EuroQol: the current state of play. Health Policy 
1996;37:53–72.
49. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health 
states: development and testing of the D1 valuation model. Med 
Care 2005;43:203–20.
50. Kitamura K, Kangawa K, Kojima M, Ichiki Y, Matsuo H, Eto 
T. Complete amino acid sequence of porcine adrenomedul-
lin and cloning of cDNA encoding its precursor. FEBS Lett 
1994;338:306–10.
51. Temmesfeld-Wollbruck B, Hocke AC, Suttorp N, Hippenstiel S. 
Adrenomedullin and endothelial barrier function. Thromb Hae-
most 2007;98:944–51.
52. Hao SL, Yu ZH, Qi BS, Luo JZ, Wang WP. The antifibrosis effect 
of adrenomedullin in human lung fibroblasts. Exp Lung Res 
2011;37:615–26.
53. Marinoni E, Pacioni K, Sambuchini A, Moscarini M, Letizia C, DI 
Iorio R. Regulation by hypoxia of adrenomedullin output and 
expression in human trophoblast cells. Eur J Obstet Gynecol 
Reprod Biol 2011;154:146–50.
54. Martinez A, Miller MJ, Unsworth EJ, Siegfried JM, Cuttitta F. 
Expression of adrenomedullin in normal human lung and in 
pulmonary tumors. Endocrinology 1995;136:4099–105.
55. Eto T. A review of the biological properties and clinical implica-
tions of adrenomedullin and proadrenomedullin N-terminal 
20 peptide (PAMP), hypotensive and vasodilating peptides. 
Peptides 2001;22:1693–711.
56. Linscheid P, Seboek D, Zulewski H, Keller U, Muller B. Autocrine/
paracrine role of inflammation-mediated calcitonin gene-related 
peptide and adrenomedullin expression in human adipose tis-
sue. Endocrinology 2005;146:2699–708.
57. Stolz D, Kostikas K, Blasi F, Boersma W, Milenkovic B, Lacoma A, 
et al. Adrenomedullin refines mortality prediction by the BODE 
index in COPD: the “BODE-A” index. Eur Respir J 2014;43:397–
408.
58. Pfeil U, Aslam M, Paddenberg R, Quanz K, Chang CL, Park 
JI, et al. Intermedin/adrenomedullin-2 is a hypoxia-induced 
endothelial peptide that stabilizes pulmonary microvas-
cular permeability. Am J Physiol Lung Cell Mol Physiol 
2009;297:L837–45.
59. Di Paola R, Talero E, Galuppo M, Mazzon E, Bramanti P, 
Motilva V, et al. Adrenomedullin in inflammatory process 
associated with experimental pulmonary fibrosis. Respir Res 
2011;12:41.
60. Qi JG, Ding YG, Tang CS, Du JB. Chronic administration of adre-
nomedullin attenuates hypoxic pulmonary vascular structural 
remodeling and inhibits proadrenomedullin N-terminal 20-pep-
tide production in rats. Peptides 2007;28:910–9.
61. Haviv M, Haver E, Lichtstein D, Hurvitz H, Klar A. Atrial natriu-
retic peptide in children with pneumonia. Pediatr Pulmonol 
2005;40:306–9.
62. Vesely DL. Atrial natriuretic peptide prohormone gene expres-
sion: hormones and diseases that upregulate its expression. 
IUBMB Life 2002;53:153–9.
63. Aiura K, Ueda M, Endo M, Kitajima M. Circulating concentrations 
and physiologic role of atrial natriuretic peptide during endo-
toxic shock in the rat. Crit Care Med 1995;23:1898–906.
Brought to you by | Universitaetsbibliothek Basel
Authenticated
Download Date | 4/29/19 4:29 PM
